Plant-made or "biofarmed" viral vaccines are some of the earliest products of 
the technology of plant molecular farming, and remain some of the brightest 
prospects for the success of this field. Proofs of principle and of efficacy 
exist for many candidate viral veterinary vaccines; the use of plant-made viral 
antigens and of monoclonal antibodies for therapy of animal and even human viral 
disease is also well established. This review explores some of the more 
prominent recent advances in the biofarming of viral vaccines and therapies, 
including the recent use of ZMapp for Ebolavirus infection, and explores some 
possible future applications of the technology.